What You Need to Know Ahead of Viatris' Earnings Release

Core Insights - Viatris Inc. (VTRS) is set to announce its fiscal third-quarter earnings for 2025 on November 6, with a market cap of $12.1 billion and a focus on producing medicines for various therapeutic areas [1] Financial Performance - Analysts expect VTRS to report a profit of $0.63 per share for Q3 2025, reflecting a 16% decrease from $0.75 per share in the same quarter last year [2] - For the full fiscal year, VTRS is projected to report an EPS of $2.31, down 12.8% from $2.65 in fiscal 2024, but is expected to see a 5.2% increase in EPS to $2.43 in fiscal 2026 [3] Stock Performance - VTRS stock has underperformed the S&P 500 Index, which gained 16.2% over the past 52 weeks, with VTRS shares down 10.7% during the same period [4] - The stock also underperformed the Health Care Select Sector SPDR Fund, which saw a 2.9% dip [4] Recent Developments - On August 7, VTRS shares rose by 7.3% after reporting Q2 results, with an adjusted EPS of $0.62 surpassing Wall Street expectations of $0.56, while revenue was reported at $3.6 billion, down 5.6% year-over-year [5] - The company anticipates full-year adjusted EPS between $2.16 and $2.30, with revenue expected to be in the range of $13.5 billion to $14 billion [5] Analyst Ratings - The consensus opinion on VTRS stock is cautious, with a "Hold" rating overall; out of nine analysts, two recommend a "Strong Buy," six a "Hold," and one a "Moderate Sell" [6] - The average analyst price target for VTRS is $11.91, indicating a potential upside of 15.5% from current levels [6]